Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
02/2012
02/16/2012WO2012020170A1 Novel 6,7-disubstituted-isoquinoline derivatives and their use
02/16/2012WO2012020134A1 Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
02/16/2012WO2012020133A1 Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
02/16/2012WO2012020130A1 Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
02/16/2012WO2012020022A1 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
02/16/2012WO2012019984A1 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
02/16/2012WO2012019970A1 Combination of glyt1 compound with antipsychotics
02/16/2012WO2012019954A1 Pyrazolopyridine compounds as pde10a inhibitors
02/16/2012WO2012019439A1 Huperzine a ophthalmic microemulsion and preparation method thereof
02/16/2012WO2012019428A1 Benzohydrol derivatives, a preparation process and pharmaceutical use thereof
02/16/2012WO2012019315A1 Novel trpv3 modulators
02/16/2012WO2011143360A3 Compositions, methods and systems for the synthesis and use of imaging agents
02/16/2012WO2011141824A9 Methods for identifying nmda receptor modulators
02/16/2012WO2011140655A8 Phenolic compositions derived from apple skin and uses thereof
02/16/2012WO2011131693A3 Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
02/16/2012US20120041071 Tapentadol for treating pain due to osteoarthritis
02/16/2012US20120041068 Extended Release Pharmaceutical Preparations for Active Pharmaceutical Ingredients with pH Dependent Solubility
02/16/2012US20120041066 Medical foods for the treatment of developmentally-based neuropsychiatric disorders via modulation of brain glycine and glutathione pathways
02/16/2012US20120041061 Use of prodrugs of gaba analogs for treating diseases
02/16/2012US20120041045 Use of pharmaceutical compositions containing mesembrenone
02/16/2012US20120041036 Substituted acylguanidine derivatives (as amended)
02/16/2012US20120041034 Sustained release aminopyridine composition
02/16/2012US20120041033 Hydroxybenzoate salts of metanicotine compounds
02/16/2012US20120041031 Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists
02/16/2012US20120041028 Benzimidazoles which have activity at m1 receptor and their uses in medicine
02/16/2012US20120041027 Benzimidazoles which have activity at m1 receptor and their uses in medicine
02/16/2012US20120041026 (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors
02/16/2012US20120041023 Small molecule activators of mitochondrial function
02/16/2012US20120041018 Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor
02/16/2012US20120041017 Pyridocarbazole type compounds and applications thereof
02/16/2012US20120041014 Methods of Converting a Patient's Treatment Regimen from Intravenous Administration of an Opioid to Oral Co-Administration of Morphine and Oxycodone Using a Dosing Algorithm to Provide Analgesia
02/16/2012US20120041012 Substituted spirocyclic amines useful as antidiabetic compounds
02/16/2012US20120041011 Substituted benzofused derivatives and their use as vanilloid receptor ligands
02/16/2012US20120041010 Pharmaceutical combination of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3r,5s)-3,5-dihydroxyhept-6-enoic acid and candesartan
02/16/2012US20120041004 Fused pyrimidine-dione derivatives as trpai modulators
02/16/2012US20120041002 Substituted pyrazolo [1,5-a] pyrimidines as metabotropic glutamate antagonists
02/16/2012US20120040998 2-alkyl piperidine mglur5 receptor modulators
02/16/2012US20120040997 Vinyl-aryl derivatives for inflammation and immune-related uses
02/16/2012US20120040993 Neuroprotective multifunctional compounds and pharmaceutical compositions comprising them
02/16/2012US20120040992 Oligooxopiperazines and methods of making and using them
02/16/2012US20120040991 3-azabicyclo [4.1.0] heptanes used as orexin antagonists
02/16/2012US20120040990 Indol-3-y-carbonyl-piperidin and piperazin-derivatives
02/16/2012US20120040987 Derivatives of 6-(6-nh-substituted-triazolopyridazine-sulfanyl) benzothiazoles and benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors
02/16/2012US20120040984 Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof
02/16/2012US20120040983 Phthalazine Compounds as P38 Map Kinase Modulators and Methods of Use Thereof
02/16/2012US20120040980 Quinazolinone compounds
02/16/2012US20120040979 Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions
02/16/2012US20120040978 Heterocyclic Fused Cinnoline M1 Receptor Positive Allosteric Modulators
02/16/2012US20120040976 Small molecule immunomodulators for alzheimer's disease
02/16/2012US20120040972 Dual modulators of 5ht2a and d3 receptors
02/16/2012US20120040970 Intranasal delivery system for dantrolene
02/16/2012US20120040969 N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
02/16/2012US20120040965 Substituted azepino[4,3-b]indoles, pharmacological composition and a method for the production and use thereof
02/16/2012US20120040964 N-substituted piperidines and their use as pharmaceuticals
02/16/2012US20120040961 Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
02/16/2012US20120040952 Azetidines as histamine h3 receptor antagonists
02/16/2012US20120040951 Heteroaryl compounds useful as raf kinase inhibitors
02/16/2012US20120040950 Isoindolinone inhibitors of phosphatidylinositol 3-kinase
02/16/2012US20120040948 Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
02/16/2012US20120040947 Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
02/16/2012US20120040941 5-(2--1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases
02/16/2012US20120040940 Combination of pilocarpin and methimazol for treating charcot-marietooth disease and related disorders
02/16/2012US20120040939 Medicinal use of 5-benzylaminosalicylic acid derivative or its salt
02/16/2012US20120040935 Compositions useful as inhibitors of voltage-gated ion channels
02/16/2012US20120040933 9-(piperazinylalkyl) carbazoles as bax-modulators
02/16/2012US20120040930 Tetracyclic terpene series compounds, methods for preparing same, uses thereof as medicines and pharmaceutical compounds containing same
02/16/2012US20120040923 Stable s-adenosyl-l-methionine
02/16/2012US20120040911 Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
02/16/2012US20120040910 Methods of preventing or treating brain diseases
02/16/2012US20120040900 Compositions of and methods of using ligand dimers
02/16/2012US20120040897 Novel derivatives of acyl cyanopyrrolidines
02/16/2012US20120040886 Analogues of Neuropeptide Y Having Proline Substitution At Position 34
02/16/2012US20120040885 Analogues of Neuropeptide Y Having At Least One Synthetic Amino Acid Substitution
02/16/2012US20120040029 Composition comprising oil palm phenolics for use in providing neuroprotective effects and cognitive-enhancement
02/16/2012US20120040028 Compositions And Methods For Promoting A Relaxation State
02/16/2012US20120040027 Food or beverage composition comprising unroasted coffee solids
02/16/2012US20120040014 LIPID Supplements for Maintaining Health and Treatment of Acute and Chronic Disorders
02/16/2012US20120040012 Therapeutic stem cell nutrient composition and uses thereof
02/16/2012US20120040009 Particulate pharmaceutical composition with an opioid and an opioid antagonist
02/16/2012US20120040008 Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
02/16/2012US20120040006 Pharmaceutical Compositions Comprising Brivaracetam
02/16/2012US20120039999 Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
02/16/2012US20120039991 Use of apoptosis inhibiting compounds in degenerative neurological disorders
02/16/2012US20120039987 Niosome having metal porphyrin complex embedded therein, process for producing the same and drug with the use thereof
02/16/2012US20120039962 Pharmaceutical Compositions
02/16/2012US20120039958 Compositions and methods for treatment of taupathy
02/16/2012US20120039957 Optimized niacin compositions in pharmaceutical products
02/16/2012US20120039954 Method of treating insomnia
02/16/2012US20120039953 Riluzole aqueous suspensions
02/16/2012US20120039928 Medicinal plants extract using processing of herbal medicine and composition of skin external application comprising the same
02/16/2012US20120039913 Selective Histamine H4 Receptor Antagonists for the Treatment of Vestibular Disorders
02/16/2012US20120039911 Cd93 or use of soluble fragment thereof
02/16/2012US20120039909 Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
02/16/2012US20120039902 Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
02/16/2012US20120039897 Method of treatment of neurodementing diseases using isolated, monoclonal, human, anti-b-amyloid antibody
02/16/2012US20120039884 Compositions and methods for treating cardiovascular disease
02/16/2012US20120039883 Detection and diagnosis of inflammatory disorders
02/16/2012US20120039881 Compositions and methods for treating neurological disorders
02/16/2012US20120039873 Antibodies against monocyte chemotactic proteins
02/16/2012US20120039862 Extended Length Botulinum Toxin Formulation for Human or Mammalian Use
1 ... 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 ... 1833